Concurrent chemoradiation with S -1 and cisplatin on mid and upper thoracic esophageal carcinoma
10.13699/j.cnki.1001-6821.2015.03.005
- VernacularTitle:替吉奥和顺铂方案同步调强放疗治疗胸中上段及胸上段食管癌的临床研究
- Author:
Jian-Bo LI
1
;
Yi-Bo HUANG
;
Zhi-Fan ZHENG
Author Information
1. 浙江宁波明州医院 放疗科
- Keywords:
esophageal carcinoma;
S-1;
chemoradiotherapy;
adverse drug reaction
- From:
The Chinese Journal of Clinical Pharmacology
2015;(3):175-177
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of concurrent chemoradiation with S -1 and cisplatin for the treatment of locally advanced mid and upper thoracic esophageal carcinoma.Methods Forty -six patients with locally advanced mid and upper thoracic esophageal carcinoma were enrolled in this study and received two cycles of S-1 60 mg · m-2 · d -1 for 14 days and then rested for 7 days;cisplatin 25 mg · m-2 were divided into three times.Meanwhile, concurrent radiotherapy (60 Gy total, 2 Gy a day) was done.When the radiotherapy finished, patients received two more cycles of chemothera-py.The data of clinical efficacy and side effects were analyzed.Results Therewere 26 patients ( 56.5%) diagnosed with T4 and 30 patients (65.2%) with N1.The clinical response rate was 67.4%, the estimated overall survival and progression -free survival rates after 2 years were 54.5% and 45.2%, respectively.The primary adverse reactions (≥grade 2) included radiation-related esophagitis (28.3%) and neutropenia ( 37.0%).No treatment -related death occurred.Conclusion Concurrent chemoradiation with S -1 and cisplatin for the treatment of locally advanced mid and upper thoracic esophageal carcinoma exhibited encouraging results with clinically manageable adverse reactions.
